Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report
Maro Ohanian, Christian Cable, Kathleen Halka Department of Hematology/Oncology, Scott & White Healthcare and The Texas A&M Health Science Center, College of Medicine, Temple, TX, USA Objective: To describe how maintenance eculizumab sustains improved renal function in severe...
Guardado en:
Autores principales: | Halka K, Cable C, Ohanian M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4704dd7e62ae4571ad6fbff22e89e509 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome
por: Ohanian M, et al.
Publicado: (2011) -
Treatment of Shiga-Toxin Hus with Severe Neurologic Features with Eculizumab
por: Jacob H. Umscheid, et al.
Publicado: (2021) -
Uncommon presentation of atypical hemolytic uremic syndrome: A Case Report
por: Sandra M Martin, et al.
Publicado: (2021) -
Thrombotic microangiopathy after kidney transplantation: Analysis of the Brazilian Atypical Hemolytic Uremic Syndrome cohort.
por: Hong Si Nga, et al.
Publicado: (2021) -
Thrombotic microangiopathy after kidney transplantation: Analysis of the Brazilian Atypical Hemolytic Uremic Syndrome cohort
por: Hong Si Nga, et al.
Publicado: (2021)